- Home
- NMS vs NSPR Comparison
NMS vs NSPR Comparison
Compare NMS & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- NSPR
- Stock Information
- Founded
- NMS 1993
- NSPR 2005
- Country
- NMS United States
- NSPR United States
- Employees
- NMS N/A
- NSPR N/A
- Industry
- NMS Finance Companies
- NSPR Medical/Dental Instruments
- Sector
- NMS Finance
- NSPR Health Care
- Exchange
- NMS Nasdaq
- NSPR Nasdaq
- Market Cap
- NMS 68.7M
- NSPR 79.7M
- IPO Year
- NMS N/A
- NSPR N/A
- Fundamental
- Price
- NMS $11.70
- NSPR $2.56
- Analyst Decision
- NMS
- NSPR Strong Buy
- Analyst Count
- NMS 0
- NSPR 2
- Target Price
- NMS N/A
- NSPR $4.75
- AVG Volume (30 Days)
- NMS 12.0K
- NSPR 47.5K
- Earning Date
- NMS 01-01-0001
- NSPR 05-09-2025
- Dividend Yield
- NMS 4.11%
- NSPR N/A
- EPS Growth
- NMS N/A
- NSPR N/A
- EPS
- NMS N/A
- NSPR N/A
- Revenue
- NMS N/A
- NSPR $7,027,000.00
- Revenue This Year
- NMS N/A
- NSPR $28.93
- Revenue Next Year
- NMS N/A
- NSPR $172.18
- P/E Ratio
- NMS N/A
- NSPR N/A
- Revenue Growth
- NMS N/A
- NSPR 12.96
- 52 Week Low
- NMS $9.21
- NSPR $2.07
- 52 Week High
- NMS $12.18
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- NMS 47.27
- NSPR 49.83
- Support Level
- NMS $11.43
- NSPR $2.40
- Resistance Level
- NMS $11.84
- NSPR $2.79
- Average True Range (ATR)
- NMS 0.11
- NSPR 0.16
- MACD
- NMS 0.02
- NSPR 0.02
- Stochastic Oscillator
- NMS 65.85
- NSPR 60.42
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.